Satellos Bioscience Inc. (TSX:MSCL)

Canada · Delayed Price · Currency is CAD

12.34

+0.17 (1.40%)

Sep 24, 2026, 3:40 PM EST

Market Cap	261.81M +120.2%
Revenue (ttm)	n/a
Net Income	-49.15M
EPS	-2.83
Shares Out	21.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,615
Open	12.75
Previous Close	12.17
Day's Range	11.97 - 12.75
52-Week Range	7.56 - 18.98
Beta	1.14
Analysts	Buy
Price Target	17.67 (+43.19%)
Est. Earnings	Nov 13, 2026

About Satellos Bioscience

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2018

Employees 21

Stock Exchange Toronto Stock Exchange

Ticker Symbol MSCL

Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Summary

According to 3 analysts, the average rating for MSCL stock is "Buy." The 12-month stock price target is $17.67, which is an increase of 43.19% from the latest price.

Price Target

$17.67

(43.19% upside)

Analyst Consensus: Buy

Stock Forecasts

News

Satellos announces U.S. FDA cleared IND application for forazapadin

Satellos (MSLE) Bioscience announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for forazapadin for the treatment of facioscapulohumera...

19 hours ago - TheFly

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degen...

19 hours ago - GlobeNewsWire

Satellos Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Forazapadin offers a novel, non-genetic approach to DMD by targeting muscle stem cell regeneration, with promising early clinical results and ongoing trials in both adults and children. The company is preparing for regulatory discussions and expanding into FSHD, supported by strong financials.

8 days ago - Transcripts

Satellos to Present at the 31st Annual Congress of the World Muscle Society

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...

9 days ago - GlobeNewsWire

Satellos Bioscience Slides: Corporate presentation

Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.

14 days ago - Filings

Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

The conference highlighted forazapadin's novel approach to muscle regeneration in Duchenne and FSHD, with two phase II trials set to deliver key data by early next year. Early results show functional and biomarker improvements, and expansion into FSHD is planned.

15 days ago - Transcripts

Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ...

Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market Signals

15 days ago - GuruFocus

Satellos Names Forazapadin As INN For Lead DMD Drug Candidate

(RTTNews) - Satellos Bioscience Inc. (MSLE) announced that the World Health Organization has assigned the International Nonproprietary Name (INN) forazapadin to its lead drug candidate, previously kno...

15 days ago - Nasdaq

Satellos assigns forazapadin name to SAT-3247

Satellos (MSLE) announced the assignment of the International Nonproprietary Name, or INN, “forazapadin” for the company’s orally administered, small molecule drug candidate designed to restore muscle...

15 days ago - TheFly

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle dis...

15 days ago - Financial Post

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle di...

15 days ago - GlobeNewsWire

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management...

23 days ago - BNN Bloomberg

Satellos to Participate in Upcoming Investor Conferences

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...

23 days ago - GlobeNewsWire

Satellos initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Satellos (MSLE) with an Outperform rating and $22 price target

4 weeks ago - TheFly